Skip to Content

'
Cathy Eng, M.D., FACP

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Department of Gastrointestinal (GI) Medical Oncology, Network Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Colorectal Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Hahnemann University School of Medicine, Philadelphia, PA, MD, Doctorate of Medicine
1990 New York University, New York, NY, BA, Psychobiology and International Politics (Minor)

Postgraduate Training

7/1999-6/2002 Fellowship, Hematology/Oncology, University of Chicago Medical Center, Chicago, IL

Experience/Service

Other Appointments/Responsibilities

Co-Chairman, SWOG Rectal Subcommittee, Houston, TX, 2012-present
Member, ASCO Government Relations Committee, Houston, TX, 2012-present
Member, ASCO GI Cancers Symposium, Steering Committee, Houston, TX, 2012-2015
Member, NCI Colon Task Force of the GI Steering Committee, Houston, TX, 2010-present
Member, NCI Rectal-Anal Task Force of the GI Steering Committee, Houston, TX, 2010-present

Honors and Awards

2013-2016 Endowment from the Decker and Lou Dawson Family
2011-2012 ASCO Leadership Development Program

Selected Publications

Peer-Reviewed Original Research Articles

1. Ahmed S, Eng C. Optimal management of squamous cell carcinoma of the anal canal: where are we now? Expert Review of Anticancer Therapy. In Press.
2. Lieu C, Rentfro L, de Gramont A, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent D, Eckhardt SG, Eng C. The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program. Journal of Clinical Oncology (JCO). In Press.
3. Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt N, Mitchell EP, Davidenko I, Stephenson J, Elez ME, Prenen H, Deng H, Tang R, McCaffery I, Oliner K, Chen L, Gansert JL, Loh E, Smethurst D, Tabernero J. Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab With Panitumumab Versus Panitumumab Alone in Patients With Wild-Type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research. e-Pub 6/2014. PMID: 24919569.
4. Blackham AU, Swett K, Eng C, Sirintrapun S, BErgman S, Geisinger K, Votanopoulos K, Stewart JH, Shen J, Levine EL. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 12/2013. e-Pub 12/2013.
5. Das P, Eng C, Rodriguez-Bigas M, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SK, GArrett C, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab and erlotinib for rectal cancer: A phase I trial. Int J Radiat Oncol Biol Phys, 12/2013. PMID: 24315563.
6. Eng C, Chang GJ, You N, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane C. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer 119(21), 11/2013.
7. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishan S, Delclos ME, Crane CH, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: Outcomes and toxicity. Am J Clin Oncol, 3/2013.
8. Liu SV, Lenkiewicz E, Evers L, Holley T, Kiefer J, Ruiz C, Bubbendorf L, Demeure M, Eng C, Ramanathan RM, Von Hoff DD, Barrett MT. Clonal analysis for identification of molecular pathways with potential therapeutic implications in rare gastrointestinal and endocrine cancers. Phys Biol 9(6). e-Pub 11/2012.
9. Lin M, Eng C, Hawk E, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in colorectal cancer patients. Cancer, 6/2012.
10. Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int Journal of Surg Onc. e-Pub 5/2012. PMCID: PMCPMC3362864.
11. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. e-Pub 4/2012.
12. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM. Subclinical neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. e-Pub 4/2012.
13. Lin M, Eng C, Hawk E, Huang M, Lie J, Griesinger A, Gu J, Ellis, LM, Wu X. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis, 2/2012. PMID: 22318908.
14. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated with Surgical Oophorectomy in Patients with Metastatic Colorectal Cancer to the Ovary. Clin Colorectal Cancer, 1/2012. PMID: 22280844.
Other Articles
1. Rogers JE, Crane CH, Das P, Delclos M, Gould Jr., MS, Ohanata A, Malatek D, Eng C. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. In Press.

Abstracts

1. Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt TC, Mitchell EP, Davidenko I, Oliner K, Chen L, Huang J, McCaffery I, Loh E, Smethurt D, Tabernero J. A Randomized, phase Ib/II trial of rilotumumab (AMG 102;ril) or ganitumab (AMG 479;gan) with panitumumab (pmab) vs pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. ASCO, Clinical Science Symposium 2011, 1/2011.
2. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. 2011 Gastrointestinal Cancer Symposium, 1/2011.
3. Eng C, Bendell JC, Bessudo A, Gabrail NY, Diamon J, Pande AU, Gorbatchevsky I. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 1977, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. 2011 Gastrointestinal Cancer Symposium, 1/2011.
4. Dawood SS, Gonzalez-Angulo AM, Eng C. Prognostic impact of baseline CEA level and surgery of primary tumor among patients with stage IV de novo colon cancer. 2011 Gastrointestinal Cancer Symposium, 1/2011.
5. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). 2011 Gastrointestinal Cancer Symposium, 1/2011.
6. Wang XS, Eng C, Fogelman DR, Malekifar M, Liao KE, Glover KY, Cleeland CS. Self-report neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab. 2011 Gastrointestinal Cancer Symposium, 1/2011.

Grant & Contract Support

Title: NCTN: NCI Clinical Trials Network - Lead Academic Participaiting Sites (LAPS)
Funding Source: NCI
Role: Principal Investigator
Duration: 4/2014 - 2/2019
 
Title: Reducing peripheral neuropathy in underserved colorectal cancer patients by minocycline
Funding Source: American Cancer Society (ACS)
Role: Co-Investigator
Principal Investigator: Shelley Wang
Duration: 9/2013 - 8/2017
 
Title: Susceptibility markers for a breast-colon cancer family phenotype
Funding Source: NIH K07
Role: Co-Mentor
Principal Investigator: Mala Pande
Duration: 9/5/2012 - 9/5/2017
 
Title: A Phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.
Funding Source: SWOG/Alliance
Role: SWOG Principal Investigator
Principal Investigator: George Chang
Duration: 7/23/2012 - 12/31/2017
 
Title: Phase III randomized study of adjuvant FOLFOX chemotherapy comprising oxaliplatin, leucovorin calcium, and fluorouracil with versus without celecoxib in patients with resected stage III colon cancer.
Funding Source: CALGB 80702
Role: Principal Investigator
Duration: 6/15/2010 - 12/31/2019
 
Title: A randomized, placebo-controlled, Phase 1/2 Study of ARQ197 in combination with Irinotecan and Cetuximab in subjects with metastatic colorectal cancer with Wild-Type KRAS who have received front-line systemic therapy
Funding Source: Daiichi Pharmaceutical Corporation
Role: Principal Investigator
Duration: 4/8/2010 - 5/31/2013
 
Title: SWOG U10 Insitutional Grant
Funding Source: NCI
Role: Principal Investigator
Duration: 1/2010 - 12/2015
 
Title: Prognostic molecular and environmental markers in high-risk stage II/III colon cancer
Funding Source: Urbieta Family Colon Cancer Research Fund
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2011
 
Title: An International Multicentre Open Label Randomized Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease
Funding Source: ECOG 2183: InterAACT (collaboration of IRCI/NCI/EORTC)
Role: Principal Investigator
 
Title: A Phase III Clinical Trial Evaluating TheraSpheres® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy
Funding Source: 2012-0192
Role: Co-Principal Investigator
Principal Investigator: Armeen Mahvash

Last updated: 6/11/2014